FindTrial
Sign In

Tumour Biomarkers in Pterygium

Comparative study to correlate expression of p53 and Ki67 proteins in patients with severity & duration of pterygium

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/04/013493
Enrollment
30
Registered
2018-04-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patients with pterygium

Interventions

Control Intervention1: p53 and ki67 protiens: p53 and ki67 protiens in severity and duration of pterygium patients

Sponsors

All India Institute of Medical SciencesRishikesh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Males and females of any age group 2. Case of primary pterygium.

Exclusion criteria

Exclusion criteria: 1. Any conjunctival and systemic malignancy 2. Any previous ocular surgery(squint, cataract) 3. Previously treated pterygium with mitomycin 4. Any case of recurrent pterygium 5. Patients with moderate to severe dry eye 6. History of any chemical exposure 7. pseudopterygium

Design outcomes

Primary

MeasureTime frame
Outcome parameters shall be relation of quantitative (low grade, moderate grade, high grade) p53 and Ki-67 expression with that of severity and duration of pterygiumTimepoint: on day 1 postop—

Secondary

MeasureTime frame
comparison of p53 and Ki-67 expression in moderate and severe group and between 4 years and 4 years duration of pterygiumTimepoint: 1 year—

Countries

India

Contacts

Public ContactDr Sanjeev Kumar Mittal

AIIMS RISHIKESH

sunitasanjeevmittal@yahoo.co.in9412909375

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026